Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRANK-111
- Development stage
- Preclinical
- Lead developer
- MindRank
- Modality
- Small Molecules
01
Overview
MRANK-111 is a small molecule modulator of the Cannabinoid receptor 1 (CB1R) currently under development by MindRank for the treatment of obesity. As a CB1R-targeted agent, it is designed to interact with the endocannabinoid system, which is a critical regulator of energy balance, appetite, and metabolic homeostasis. While the specific functional profile (e.g., antagonist or inverse agonist) has not been publicly detailed, the program is positioned within MindRank's pipeline of AI-discovered metabolic therapies. It is currently in the early stages of preclinical development, specifically within the discovery and optimization phases.
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on MRANK-111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRANK-111.